Exclusive special offer and discount title banner vector image

GLOBAL HEPARIN MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

Global Heparin Market by Heparin Type (Low Molecular Weight Heparin, Ultra Low Molecular Weight Heparin, Unfractionated Heparin) Market by Route of Administration (Intravenous, Subcutaneous) Market by Application (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, Other Applications) Market by Source (Porcine, Bovine, Other Sources) Market by End Use (Outpatient, Inpatient) by Geography

REQUEST CUSTOMIZATION

MARKET OVERVIEW

In terms of revenue, the global heparin market is expected to grow with a CAGR of 4.01% during the forecast period, 2024 to 2032. The market study has also analyzed the impact of COVID-19 on the heparin market qualitatively as well as quantitatively.  

Heparin is an organic substance consisting of a complex collection of molecules related to carbohydrates and is mainly used in labs to stop blood coagulation in blood samples. Found in the lungs and liver by nature, the primary varieties of heparin include unfractionated and low molecular weight heparin. 

Moreover, heparin’s anticlotting ability has led to its widespread usage in the treatment of heart, lung, and circulation problems where there is a high risk of blood clotting. It is used for preventing blood clotting in the heart or blood vessels during and after surgery, as well.

Heparin Market

Read our latest blog on the Heparin  Market

GROWTH ENABLERS

Key growth enablers of the global heparin market:

  • Increasing cases of cardiovascular and chronic diseases
  • Rising aging population
    • As the world’s population ages, there is a growing demand for healthcare solutions targeted to the special needs of older persons. According to the World Health Organization, the proportion of older adults worldwide will nearly double from 12% to 22% between 2015 and 2050, with 1 in 6 of the global population aged 60 or older by 2030.
    • The heparin market is highlighted here, which is expected growth as the population ages. As individuals get older, chronic obstructive pulmonary disease (COPD), atrial fibrillation, and coronary artery disease become more common. Since anticoagulant therapy is usually required for various illnesses, heparin may be a necessary medicine, thus boosting the market’s growth.
  • Increasing application in various medical conditions

GROWTH RESTRAINTS

Key restraining factors of the global heparin market growth: 

  • Cost fluctuations of raw heparin
    • From mucosal extraction to purification and processing, heparin manufacture involves multiple processes. Each phase necessitates the use of specialized equipment, competent workers, and specific inputs, all of which contribute to overall resource consumption. As a result, its cost can fluctuate based on the cost of inputs and the effectiveness of production.
    • Changes in animal availability may also have an impact on the market since heparin manufacturing mostly relies on the intestinal mucosa of pigs or cows. 
    • Animal-derived heparin continues to be the main cost factor, even though synthetic heparin and recombinant manufacturing techniques are being investigated but are not yet widely used.
  • Competition from alternative anticoagulants  
  • Bleeding risks and monitoring requirements

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Heparin Market | Top Trends 

  • Low molecular weight heparins (LMWHs) are becoming more popular as they offer advantages such as a longer half-life, reduced bleeding risks, and convenient subcutaneous administration, making them preferable to unfractionated heparin. 
  • The assessment of heparin’s potential beyond conventional indications such as venous thromboembolism and cardiovascular disorders is intensifying as the drug is used more frequently in medical surgeries. Research into its potential use in illnesses such as sepsis, cancer, and kidney ailments further opens up new opportunities for market growth. 

MARKET SEGMENTATION

Market Segmentation – Heparin Type, Route of Administration, Application, Source, and End-Use – 

Market by Heparin Type: 

  • Low Molecular Weight Heparin 
    • Light-molecular weight heparin (LMWH) is an anticoagulant drug that lowers the risk of blood clots and diseases such as pulmonary embolism and deep vein thrombosis (DVT). As LMWH is derived from unfractionated heparin (UFH), its molecules are smaller than those of ordinary heparin, which makes it easier to use and reduces the possibility of some negative effects. 
    • LMWH requires fewer injections because it is active in the body for a longer amount of time than unfractionated heparin. It lowers the possibility of missing doses and is convenient for patients.
    • This heparin type is a safe, efficient anticoagulant drug that has a number of benefits. In addition to greatly enhancing patient outcomes, it is essential for the prevention and management of a number of thromboembolic illnesses.
  • Ultra Low Molecular Weight Heparin
  • Unfractionated Heparin 

Market by Route of Administration:

  • Intravenous
      • Heparin has historically been administered most frequently by Intravenous. Heparin is administered intravenously (IV), where it enters the bloodstream directly and has the fastest rate of absorption and commencement of effect. This is important when an anticoagulant effect is required quickly, such as in an emergency. 
      • Patients using IV heparin require close monitoring in a hospital setting due to the drug’s quick action and risk of bleeding problems. This can be resource-intensive and restrict patient autonomy. IV heparin therapy can be more costly than other methods, such as subcutaneous (SC), because of hospital stays, the need for monitoring, and the need to dispose of medical equipment.
  • Subcutaneous 

Market by Application:

  • Venous Thromboembolism
  • Atrial Fibrillation
  • Renal Impairment
  • Coronary Artery Disease
  • Other Applications

Market by Source:

  • Porcine 
  • Bovine
  • Other Sources

Market by End Use:

  • Outpatient
  • Inpatient

GEOGRAPHICAL STUDY

Geographical Study Based on Four Major Regions: 

  • North America: The United States and Canada
    • In North America, the prevalence of thromboembolic and cardiovascular diseases is rising. In the US, cardiovascular disease claims one life every 33 seconds, according to the Centers for Disease Control and Prevention (CDC).
    • The presence of key pharmaceutical companies such as Pfizer, Baxter, and Aspen Pharmacare holds significant market positions, contributing to the growth of the Heparin market in North America.
    • North America’s heparin market is expected to remain active, owing to ongoing advancements in the field, the rising demand for effective anticoagulants, and a focus on personalized medicine.
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Nordic Countries, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Thailand, Australia & New Zealand, and Rest of Asia-Pacific 
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global heparin market:

  • Pfizer Inc
  • B. Braun Medical Inc
  • Dr. Reddy’s Laboratories Ltd
  • Aspen Pharmacare Holdings Limited
  • Opocrin SpA
  • Techdow USA
  • Fresenius SE & Co KGaA

Key strategies adopted by some of these companies:

  • In March 2023, Techdow USA announced FDA approval for Generic Lovenox (Enoxaparin Sodium) to be used in prefilled syringes for the United States market. 
  • In January 2022, Optimvia collaborated with Ginkgo Bioworks to improve the manufacturing efficiency of biosynthetic heparin.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedHeparin Type, Route of Administration, Application, Source, and End Use
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed

Aspen Pharmacare Holdings Limited, B. Braun Medical Inc, Baxter International Inc, Bioiberica SAU, Dr. Reddy’s Laboratories Ltd, Fresenius SE & Co KGaA, Gland Pharma Limited GSK PLC, Hebei Changshan Biochemical Pharmaceutical Co Ltd, Hikma Pharmaceuticals, LEO Pharma AS, Novartis AG, Opocrin SpA, Pfizer Inc, Techdow USA

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASING CASES OF CARDIOVASCULAR AND CHRONIC DISEASES
      2. RISING AGEING POPULATION
      3. INCREASING APPLICATION IN VARIOUS MEDICAL CONDITIONS
    2. KEY RESTRAINTS
      1. COST FLUCTUATIONS OF RAW HEPARIN
      2. COMPETITION FROM ALTERNATIVE ANTICOAGULANTS
      3. BLEEDING RISKS AND MONITORING REQUIREMENTS
  4. KEY ANALYTICS
    1. PARENT MARKET ANALYSIS
    2. KEY MARKET TRENDS
      1. PERSONALIZATION AND TARGETED THERAPIES
      2. EXPLORATION OF EMERGING APPLICATIONS
      3. ADVANCEMENTS IN TECHNOLOGY
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. MARKET MATURITY ANALYSIS
    5. GROWTH PROSPECT MAPPING
    6. MARKET CONCENTRATION ANALYSIS
    7. REGULATORY FRAMEWORK
    8. KEY BUYING CRITERIA
      1. EFFECTIVENESS AND SAFETY
      2. EASE OF USE AND ADMINISTRATION
      3. AVAILABILITY AND SUPPLY
      4. COST
  5. MARKET BY HEPARIN TYPE
    1. LOW MOLECULAR WEIGHT HEPARIN
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. ULTRA LOW MOLECULAR WEIGHT HEPARIN
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. UNFRACTIONATED HEPARIN 
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY ROUTE OF ADMINISTRATION 
    1. INTRAVENOUS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. SUBCUTANEOUS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY APPLICATION
    1. VENOUS THROMBOEMBOLISM
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. ATRIAL FIBRILLATION
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. RENAL IMPAIRMENT
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. CORONARY ARTERY DISEASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    5. OTHER APPLICATIONS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. MARKET BY SOURCE
    1. PORCINE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. BOVINE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. OTHER SOURCES
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  9. MARKET BY END USE
    1. OUTPATIENT
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. INPATIENT 
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  10. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA HEPARIN MARKET DRIVERS
      3. NORTH AMERICA HEPARIN MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA HEPARIN MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES HEPARIN MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA HEPARIN MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE HEPARIN MARKET DRIVERS
      3. EUROPE HEPARIN MARKET CHALLENGES
      4. KEY PLAYERS IN EUROPE HEPARIN MARKET
      5. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM HEPARIN MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY HEPARIN MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE HEPARIN MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY HEPARIN MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN HEPARIN MARKET SIZE & OPPORTUNITIES
        6. NORDIC COUNTRIES
          1. NORDIC COUNTRIES HEPARIN MARKET SIZE & OPPORTUNITIES
        7. REST OF EUROPE
          1. REST OF EUROPE HEPARIN MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES 
      2. ASIA-PACIFIC HEPARIN MARKET DRIVERS
      3. ASIA-PACIFIC HEPARIN MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC HEPARIN MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA HEPARIN MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN HEPARIN MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA HEPARIN MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA HEPARIN MARKET SIZE & OPPORTUNITIES
        5. THAILAND
          1. THAILAND HEPARIN MARKET SIZE & OPPORTUNITIES
        6. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND HEPARIN MARKET SIZE & OPPORTUNITIES
        7. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC HEPARIN MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD HEPARIN MARKET DRIVERS
      3. REST OF WORLD HEPARIN MARKET CHALLENGES
      4. KEY PLAYERS IN REST OF WORLD HEPARIN MARKET
      5. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA HEPARIN MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA HEPARIN MARKET SIZE & OPPORTUNITIES
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ASPEN PHARMACARE HOLDINGS LIMITED
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      2. B. BRAUN MEDICAL INC
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      3. BAXTER INTERNATIONAL INC
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      4. PFIZER INC
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      5. FRESENIUS SE & CO KGAA
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      6. DR. REDDY’S LABORATORIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      7. GLAXOSMITHKLINE PLC
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      8. HEBEI CHANGSHN BIOCHEMICAL PHARMACEUTICAL CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      9. HIKMA PHARMACEUTICALS
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      10. OPOCRIN SPA 
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
        3. STRENGTHS & CHALLENGES
      11. LEO PHARMA AS
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
      12. GLAND PHARMA
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
      13. NOVARTIS AG
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
      14. BIOIBERICA SAU 
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST
      15. TECHDOW USA
        1. COMPANY OVERVIEW
        2. PRODUCTS LIST

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – HEPARIN

TABLE 2: GLOBAL HEPARIN MARKET, BY HEPARIN TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL HEPARIN MARKET, BY HEPARIN TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 4: GLOBAL LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 6: GLOBAL ULTRA LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL ULTRA LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 8: GLOBAL UNFRACTIONATED HEPARIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL UNFRACTIONATED HEPARIN MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 10: GLOBAL HEPARIN MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL HEPARIN MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 12: GLOBAL INTRAVENOUS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL INTRAVENOUS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 14: GLOBAL SUBCUTANEOUS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL SUBCUTANEOUS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 16: GLOBAL HEPARIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL HEPARIN MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 18: GLOBAL VENOUS THROMBOEMBOLISM MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL VENOUS THROMBOEMBOLISM MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 20: GLOBAL ATRIAL FIBRILLATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL ATRIAL FIBRILLATION MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 22: GLOBAL RENAL IMPAIRMENT MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL RENAL IMPAIRMENT MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 24: GLOBAL CORONARY ARTERY DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL CORONARY ARTERY DISEASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 26: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 28: GLOBAL HEPARIN MARKET, BY SOURCE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: GLOBAL HEPARIN MARKET, BY SOURCE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 30: GLOBAL PORCINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: GLOBAL PORCINE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 32: GLOBAL BOVINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 33: GLOBAL BOVINE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 34: GLOBAL OTHER SOURCES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 35: GLOBAL OTHER SOURCES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 36: GLOBAL HEPARIN MARKET, BY END USE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 37: GLOBAL HEPARIN MARKET, BY END USE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 38: GLOBAL OUTPATIENT MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 39: GLOBAL OUTPATIENT MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 40: GLOBAL INPATIENT MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 41: GLOBAL INPATIENT MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 42: GLOBAL HEPARIN MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 43: GLOBAL HEPARIN MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 44: NORTH AMERICA HEPARIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 45: NORTH AMERICA HEPARIN MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 46: KEY PLAYERS OPERATING IN NORTH AMERICA HEPARIN MARKET

TABLE 47: EUROPE HEPARIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 48: EUROPE HEPARIN MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 49: KEY PLAYERS OPERATING IN EUROPE HEPARIN MARKET

TABLE 50: ASIA-PACIFIC HEPARIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 51: ASIA-PACIFIC HEPARIN MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 52: KEY PLAYERS OPERATING IN ASIA-PACIFIC HEPARIN MARKET

TABLE 53: REST OF WORLD HEPARIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 54: REST OF WORLD HEPARIN MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 55: KEY PLAYERS OPERATING IN REST OF WORLD HEPARIN MARKET

TABLE 56: LIST OF MERGERS & ACQUISITIONS

TABLE 57: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 58: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: MARKET MATURITY ANALYSIS

FIGURE 4: GROWTH PROSPECT MAPPING FOR NORTH AMERICA

FIGURE 5: GROWTH PROSPECT MAPPING FOR EUROPE

FIGURE 6: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC

FIGURE 7: GROWTH PROSPECT MAPPING FOR REST OF WORLD

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: KEY BUYING CRITERIA

FIGURE 10: GLOBAL HEPARIN MARKET, GROWTH POTENTIAL, BY HEPARIN TYPE, IN 2023

FIGURE 11: GLOBAL HEPARIN MARKET, BY LOW MOLECULAR WEIGHT HEPARIN, 2024-2032 (IN $ MILLION)

FIGURE 12: GLOBAL HEPARIN MARKET, BY ULTRA LOW MOLECULAR WEIGHT HEPARIN, 2024-2032 (IN $ MILLION)

FIGURE 13: GLOBAL HEPARIN MARKET, BY UNFRACTIONATED HEPARIN, 2024-2032 (IN $ MILLION)

FIGURE 14: GLOBAL HEPARIN MARKET, GROWTH POTENTIAL, BY ROUTE OF ADMINISTRATION, IN 2023

FIGURE 15: GLOBAL HEPARIN MARKET, BY INTRAVENOUS, 2024-2032 (IN $ MILLION)

FIGURE 16: GLOBAL HEPARIN MARKET, BY SUBCUTANEOUS, 2024-2032 (IN $ MILLION)

FIGURE 17: GLOBAL HEPARIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023

FIGURE 18: GLOBAL HEPARIN MARKET, BY VENOUS THROMBOEMBOLISM, 2024-2032 (IN $ MILLION)

FIGURE 19: GLOBAL HEPARIN MARKET, BY ATRIAL FIBRILLATION, 2024-2032 (IN $ MILLION)

FIGURE 20: GLOBAL HEPARIN MARKET, BY RENAL IMPAIRMENT, 2024-2032 (IN $ MILLION)

FIGURE 21: GLOBAL HEPARIN MARKET, BY CORONARY ARTERY DISEASE, 2024-2032 (IN $ MILLION)

FIGURE 22: GLOBAL HEPARIN MARKET, BY OTHER APPLICATIONS, 2024-2032 (IN $ MILLION)

FIGURE 23: GLOBAL HEPARIN MARKET, GROWTH POTENTIAL, BY SOURCE, IN 2023

FIGURE 24: GLOBAL HEPARIN MARKET, BY PORCINE, 2024-2032 (IN $ MILLION)

FIGURE 25: GLOBAL HEPARIN MARKET, BY BOVINE, 2024-2032 (IN $ MILLION)

FIGURE 26: GLOBAL HEPARIN MARKET, BY OTHER SOURCES, 2024-2032 (IN $ MILLION)

FIGURE 27: GLOBAL HEPARIN MARKET, GROWTH POTENTIAL, BY END USE, IN 2023

FIGURE 28: GLOBAL HEPARIN MARKET, BY OUTPATIENT, 2024-2032 (IN $ MILLION)

FIGURE 29: GLOBAL HEPARIN MARKET, BY INPATIENT, 2024-2032 (IN $ MILLION)

FIGURE 30: NORTH AMERICA HEPARIN MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 31: UNITED STATES HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 32: CANADA HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 33: EUROPE HEPARIN MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 34: UNITED KINGDOM HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 35: GERMANY HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 36: FRANCE HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 37: ITALY HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 38: SPAIN HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 39: NORDIC COUNTRIES HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 40: REST OF EUROPE HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 41: ASIA-PACIFIC HEPARIN MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 42: CHINA HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 43: JAPAN HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 44: INDIA HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 45: SOUTH KOREA HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 46: THAILAND HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 47: AUSTRALIA & NEW ZEALAND HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 48: REST OF ASIA-PACIFIC HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 49: REST OF WORLD HEPARIN MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)

FIGURE 50: LATIN AMERICA HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FIGURE 51: MIDDLE EAST & AFRICA HEPARIN MARKET, 2024-2032 (IN $ MILLION)

FAQ’s

FAQs

A: Future growth prospects for the global heparin market include the development of novel heparin derivatives, alternative manufacturing methods, and personalized medicine approaches.

A: Intravenous and subcutaneous are the main applications enabling the demand for heparin.

A: Key technologies of Heparin include LMWH, UFH, and others.

Request Customization
Request Customization
Request free sample